IN2014MN02090A - - Google Patents

Info

Publication number
IN2014MN02090A
IN2014MN02090A IN2090MUN2014A IN2014MN02090A IN 2014MN02090 A IN2014MN02090 A IN 2014MN02090A IN 2090MUN2014 A IN2090MUN2014 A IN 2090MUN2014A IN 2014MN02090 A IN2014MN02090 A IN 2014MN02090A
Authority
IN
India
Prior art keywords
brain
medicine
anesthetic
alleviate
prevent
Prior art date
Application number
Inventor
Tomiei Kazama
Yasushi Satoh
Ryuji Yonamine
Original Assignee
Maruishi Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maruishi Pharma filed Critical Maruishi Pharma
Publication of IN2014MN02090A publication Critical patent/IN2014MN02090A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The purpose of the present invention is to provide a general anesthetic medicine which can prevent and/or alleviate an anesthetic induced neuropathy in the brain (preferably the developing brain). The present invention relates to a medicine which can prevent and/or alleviate an anesthetic induced neuropathy in the brain (preferably the developing brain) said medicine comprising a combination of a general anesthetic drug and hydrogen.
IN2090MUN2014 2012-05-31 2013-05-30 IN2014MN02090A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012125535 2012-05-31
PCT/JP2013/065094 WO2013180240A1 (en) 2012-05-31 2013-05-30 Medicine comprising combination of general anesthetic drug and hydrogen

Publications (1)

Publication Number Publication Date
IN2014MN02090A true IN2014MN02090A (en) 2015-09-04

Family

ID=49673427

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2090MUN2014 IN2014MN02090A (en) 2012-05-31 2013-05-30

Country Status (16)

Country Link
US (1) US20150079197A1 (en)
EP (1) EP2857026A4 (en)
JP (1) JP6168420B2 (en)
KR (1) KR20150018832A (en)
CN (1) CN104394873A (en)
AU (1) AU2013268366A1 (en)
BR (1) BR112014029260A2 (en)
CA (1) CA2874579A1 (en)
HK (1) HK1205450A1 (en)
IL (1) IL235718A0 (en)
IN (1) IN2014MN02090A (en)
MX (1) MX2014014543A (en)
NZ (1) NZ701553A (en)
RU (1) RU2014152690A (en)
SG (1) SG11201407489TA (en)
WO (1) WO2013180240A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6253029B2 (en) * 2015-01-21 2017-12-27 大陽日酸株式会社 Anesthesia mounting kit
US20180338995A1 (en) * 2017-05-23 2018-11-29 Perricone Hydrogen Water Company, Llc Systems and methods for treatments using hydrogen and/or noble gases
US11129848B2 (en) * 2017-08-08 2021-09-28 Perricone Hydrogen Water Company, Llc Medication enhancement using hydrogen
EP3814502A4 (en) * 2018-06-29 2022-10-05 John Mansell Compositions and methods for the treatment of anesthesia-induced neurotoxicity
US11123365B2 (en) 2019-11-18 2021-09-21 Perricone Hydrogen Water Company, Llc Compositions comprising palmitoylethanolamide and hydrogen water, and methods thereof
JP7019910B2 (en) * 2020-07-21 2022-02-16 ＭｉＺ株式会社 Compositions for preventing and / or ameliorating side effects of a drug, symptoms associated with the side effects of a drug, and / or side effects associated with treatment.
CN117861037A (en) * 2022-10-11 2024-04-12 上海氢医医疗科技有限公司 Hydrogen inhalation treatment of autism

Also Published As

Publication number Publication date
EP2857026A1 (en) 2015-04-08
CA2874579A1 (en) 2013-12-05
SG11201407489TA (en) 2014-12-30
BR112014029260A2 (en) 2017-06-27
HK1205450A1 (en) 2015-12-18
JP6168420B2 (en) 2017-07-26
RU2014152690A (en) 2016-07-20
AU2013268366A1 (en) 2015-03-19
JPWO2013180240A1 (en) 2016-01-21
CN104394873A (en) 2015-03-04
NZ701553A (en) 2016-06-24
EP2857026A4 (en) 2015-11-04
MX2014014543A (en) 2015-06-05
IL235718A0 (en) 2015-01-29
WO2013180240A1 (en) 2013-12-05
US20150079197A1 (en) 2015-03-19
KR20150018832A (en) 2015-02-24

Similar Documents

Publication Publication Date Title
IN2014MN02090A (en)
MX2015002292A (en) Methods for treating or preventing asthma by administering an il-4r antagonist.
EA201991484A1 (en) MEDICINAL FORMS OF ENZALUTAMIDE
AU349827S (en) Respirator mask
IN2015DN03029A (en)
IN2015DN03219A (en)
PH12015501071A1 (en) Combination therapy of anti-her3 antibodies
AU349826S (en) Cushion for respirator mask
MX356728B (en) Pharmaceutical combination for use in the treatment of diabetes type 2.
EA201591679A1 (en) METHOD OF NON-TOXIC TREATMENT OF ABSTINENT, CAUSED BY MEDICINE
HK1208830A1 (en) Drug delivery device for the treatment of patients with respiratory diseases
PH12016501965A1 (en) S1p modulator immediate release dosage regimen
IN2015DN00515A (en)
AU352986S (en) Nasal dilation device
PL2874600T3 (en) Pharmaceutical composition for the treatment of croakiness and sore throat
ECSP12012126A (en) MEDICINE
EA201691108A1 (en) Quinazoline-THF-Amines as PDE1 Inhibitors
MX2015013755A (en) Pharmaceutical formulation for use in the treatment and/or prevention of restenosis.
BR112015005268A2 (en) syringe containing a composition, in particular pharmaceutical, composed of immunoglobulins, their method of manufacture and their use
PH12017500923A1 (en) New dosage and use of a a2a antagonist
MX2014012535A (en) Combination therapy of anti-mif antibodies and chemotherapeutics.
MX365192B (en) Bendamustine derivatives and related compounds, and medical use thereof cancer therapy.
MX2016007947A (en) Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features.
MX356052B (en) Synergistic therapies of cannabidiol with hypothermia for neuroprotection.
IN2014KN01772A (en)